What strategies can patients use to navigate the costs associated with eculizumab treatment?

Eculizumab is an oral medication designed to block the action of endothelin, a natural substance in the body that narrows blood vessels. By inhibiting ... Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... Jul 22, 2024 ... FDA Approves Epysqli as Second Soliris Biosimilar ... The FDA approves Samsung Bioepis' Epysqli (eculizumab-aagh), marking the second US approval ... Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ... Nov 24, 2020 ... Soliris is not intended for acute treatment of a NMOSD relapse. Route of administration: Intravenous (IV) infusion. Dosage: Patients must be ... Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ... Feb 15, 2025 ... You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with eculizumab to decrease the risk that you ... Jul 14, 2017 ... What is already known about this topic? Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a ... Feb 12, 2025 ... These studies suggest that eculizumab and ravulizumab are safe and effective treatments for people with AQP4-Ab+ NMOSD.